Income Statement WuXi Biologics (Cayman) Inc. OTC Markets

Stocks

WXXW.Y

US98260N1081

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 03:59:59 2026-06-09 pm EDT			5-day change	1st Jan Change
7.600 ^USD	-2.31%		-14.36%	-5.00%

Jun. 05	Wuxi Biologics Completes Topping Out of Drug Product Facility At Singapore Crdmo Hub	CI
May. 31	Wuxi Biologics adds 69 projects in Jan-April, maintains expected revenue growth	RE

489db.BHOTqvgYWn9sAWfPAT75pUzYgojBUajRiykEy--kC2s.TSbbk5Z3GEY1d1CYNge46X6J9cylI9y28VxKitfSQj1oHaXkjSw5GCRIEA

Published financial data: WUXI BIOLOGICS (CAYMAN) INC.

Annual

Quarterly

Halfyear

YTD

LTM

Fiscal Period: December	2021	2022	2023	2024	2025
Revenues	10.29B	15.27B	17.03B	18.68B	21.79B
Total Revenues	10.29B	15.27B	17.03B	18.68B	21.79B
Cost of Goods Sold, Total	5.46B	8.54B	10.21B	11.02B	11.77B
Gross Profit	4.83B	6.72B	6.83B	7.65B	10.02B
Selling General & Admin Expenses, Total	1B	1.43B	1.79B	2.15B	2.31B
Provision for Bad Debts	132M	260M	296M	152M	205M
R&D Expenses	502M	683M	786M	766M	853M
Other Operating Expenses	24.29M	-1.49M	23.47M	-	-
Other Operating Expenses, Total	1.66B	2.37B	2.9B	3.07B	3.37B
Operating Income	3.17B	4.35B	3.93B	4.59B	6.65B
Interest Expense, Total	-39.19M	-64.38M	-158M	-158M	-143M
Interest And Investment Income	58.03M	116M	219M	352M	435M
Net Interest Expenses	18.84M	51.41M	60.69M	194M	292M
Income (Loss) On Equity Invest.	-	-	-	-	-
Currency Exchange Gains (Loss)	-32.58M	417M	46.73M	-45.22M	-267M
Other Non Operating Income (Expenses)	171M	160M	120M	192M	175M
EBT, Excl. Unusual Items	3.33B	4.98B	4.16B	4.93B	6.85B
Gain (Loss) On Sale Of Investments	665M	379M	13.83M	-91.72M	1.05B
Gain (Loss) On Sale Of Assets	-	-	-	-	-635M
EBT, Incl. Unusual Items	3.99B	5.36B	4.17B	4.83B	7.26B
Income Tax Expense	485M	808M	603M	889M	1.52B
Earnings From Continuing Operations	3.51B	4.55B	3.57B	3.95B	5.73B
Net Income to Company	3.51B	4.55B	3.57B	3.95B	5.73B
Minority Interest	-120M	-130M	-171M	-589M	-825M
Net Income - (IS)	3.39B	4.42B	3.4B	3.36B	4.91B
Net Income to Common Incl Extra Items	3.39B	4.42B	3.4B	3.36B	4.91B
Net Income to Common Excl. Extra Items	3.39B	4.42B	3.4B	3.36B	4.91B
Per Share Items
Net EPS - Basic	0.81	1.06	0.82	0.82	1.22
Basic EPS - Continuing Operations	0.81	1.06	0.82	0.82	1.22
Basic Weighted Average Shares Outstanding	4.17B	4.17B	4.16B	4.08B	4.03B
Net EPS - Diluted	0.77	1.01	0.77	0.78	1.16
Diluted EPS - Continuing Operations	0.77	1.01	0.77	0.78	1.16
Diluted Weighted Average Shares Outstanding	4.42B	4.38B	4.35B	4.23B	4.18B
Normalized Basic EPS	0.47	0.71	0.58	0.61	0.86
Normalized Diluted EPS	0.44	0.68	0.56	0.59	0.83
American Depositary Receipts Ratio (ADR)	2	2	2	2	2
Supplemental Items
EBITDA	3.62B	5.07B	4.93B	5.85B	7.92B
EBITA	3.22B	4.41B	3.99B	4.64B	6.7B
EBIT	3.17B	4.35B	3.93B	4.59B	6.65B
EBITDAR	3.63B	5.09B	4.97B	5.87B	7.94B
Effective Tax Rate - (Ratio)	12.13	15.08	14.45	18.39	21
Current Domestic Taxes	651M	777M	-	-	-
Current Foreign Taxes	-	-	-	-	-
Total Current Taxes	651M	777M	655M	1.11B	1.52B
Total Deferred Taxes	-166M	30.5M	-51.75M	-224M	3.14M
Normalized Net Income	1.96B	2.98B	2.43B	2.49B	3.45B
Interest Capitalized	64.04M	59.8M	73.71M	55.87M	15.08M
Interest on Long-Term Debt	39.97M	50.71M	80.53M	82.81M	80.66M
Supplemental Operating Expense Items
Marketing Expenses	-	-	-	-	-
Selling and Marketing Expenses	125M	163M	294M	474M	609M
General and Administrative Expenses	876M	1.27B	1.5B	1.67B	1.7B
Research And Development Expense From Footnotes	508M	690M	793M	773M	860M
Net Rental Expense, Total	9.76M	21.81M	37.08M	21.71M	15.87M
Imputed Operating Lease Interest Expense	2.11M	4.97M	15.34M	7.8M	4.99M
Imputed Operating Lease Depreciation	7.65M	16.84M	21.75M	13.91M	10.88M
Stock-Based Comp., COGS (Total)	578M	1.3B	1.42B	1.21B	966M
Stock-Based Comp., Other (Total)	-	-	-	6.6M	-
Total Stock-Based Compensation	578M	1.3B	1.42B	1.22B	966M

Fiscal Period: December	2021	2022	2023	2024	2025
Assets
Cash And Equivalents	9B	6.4B	9.67B	8.28B	9.21B
Short Term Investments	1.15B	304M	340M	1.91B	5.59B
Trading Asset Securities, Total	976M	2.01B	1.23B	524M	932M
Total Cash And Short Term Investments	11.13B	8.71B	11.24B	10.71B	15.73B
Accounts Receivable, Total	3.27B	5.16B	6.18B	5.73B	7.8B
Other Receivables	908M	617M	491M	640M	1.1B
Notes Receivable	-	-	-	-	-
Total Receivables	4.18B	5.77B	6.68B	6.37B	8.9B
Inventory	1.69B	2.28B	1.77B	1.52B	1.38B
Other Current Assets, Total	2.53B	1.7B	1.51B	4.97B	2.13B
Total Current Assets	19.53B	18.47B	21.2B	23.57B	28.14B
Gross Property Plant And Equipment	21.45B	28.4B	33.5B	32.97B	35.34B
Accumulated Depreciation	-1.7B	-2.49B	-3.56B	-4.54B	-5.59B
Net Property Plant And Equipment	19.76B	25.92B	29.94B	28.44B	29.75B
Long-term Investments	2.2B	2.71B	2.93B	2.4B	3.2B
Goodwill	1.53B	1.53B	1.53B	1.53B	1.53B
Other Intangibles, Total	601M	549M	512M	442M	467M
Accounts Receivable Long-Term	124M	109M	166M	85.66M	50.76M
Deferred Tax Assets Long-Term	221M	223M	236M	444M	501M
Other Long-Term Assets, Total	68.42M	58.88M	60.69M	66.78M	55.79M
Total Assets	44.03B	49.56B	56.58B	56.98B	63.7B
Liabilities
Accounts Payable, Total	618M	794M	1.42B	747M	1.09B
Accrued Expenses, Total	832M	998M	805M	828M	1.16B
Short-term Borrowings	-	-	-	-	-
Current Portion of Long-Term Debt	2.12B	1.32B	576M	2.44B	874M
Current Portion of Leases	104M	149M	155M	184M	382M
Current Income Taxes Payable	558M	774M	619M	648M	791M
Unearned Revenue Current, Total	1.73B	3.38B	3.09B	2.36B	2.79B
Other Current Liabilities	2.29B	1.9B	973M	1.42B	1.22B
Total Current Liabilities	8.26B	9.32B	7.64B	8.62B	8.31B
Long-Term Debt	641M	1.46B	1.57B	201M	169M
Long-Term Leases	1.43B	1.49B	2.26B	2.12B	1.68B
Unearned Revenue Non Current	877M	949M	969M	460M	341M
Deferred Tax Liability Non Current	124M	132M	123M	97.31M	139M
Other Non Current Liabilities	-	-	-	-	21.14M
Total Liabilities	11.33B	13.35B	12.56B	11.5B	10.66B
Common Stock, Total	235K	233K	235K	226K	227K
Additional Paid In Capital	27.04B	22.1B	24.49B	23.53B	22.53B
Retained Earnings	7.16B	11.58B	14.98B	18.33B	23.24B
Treasury Stock	-2.52B	-	-917M	-	-
Comprehensive Income and Other	593M	1.37B	1.78B	-46.54M	1.48B
Total Common Equity	32.28B	35.05B	40.33B	41.82B	47.25B
Minority Interest	428M	1.17B	3.69B	3.66B	5.79B
Total Equity	32.71B	36.21B	44.02B	45.48B	53.04B
Total Liabilities And Equity	44.03B	49.56B	56.58B	56.98B	63.7B
Supplemental Items
ECS Total Shares Outstanding on Filing Date	4.22B	4.23B	4.22B	4.11B	4.13B
ECS Total Common Shares Outstanding	4.22B	4.23B	4.22B	4.11B	4.13B
Book Value / Share	7.64	8.29	9.55	10.19	11.43
Tangible Book Value	30.15B	32.97B	38.29B	39.85B	45.25B
Tangible Book Value Per Share	7.14	7.8	9.07	9.7	10.95
Total Debt	4.3B	4.42B	4.56B	4.94B	3.1B
Net Debt	-6.83B	-4.29B	-6.68B	-5.77B	-12.63B
Debt Equivalent Oper. Leases	78.07M	174M	297M	174M	127M
Minority Interest, Total (Incl. Fin. Div)	428M	1.17B	3.69B	3.66B	5.79B
Equity Method Investments, Total	-	-	-	-	-
Account Code - Inventory Valuation	6	6	6	6	6
Inventories - Raw Materials, Total	1.66B	2.25B	1.74B	1.49B	1.34B
Inventories - Work In Process, Total	7.82M	10.31M	8.47M	15.41M	22.13M
Inventories - Finished Goods, Total	16.22M	20.02M	16.96M	15.93M	14.95M
Land - (BS)	2.1B	2.11B	6.2B	7.7B	7.92B
Machinery, Total	5B	6.03B	7.63B	9.39B	10.11B
Full Time Employees	9.86K	12.37K	12.74K	12.58K	13.25K
Accumulated Allowance for Doubtful Accounts (Supple)	303M	549M	757M	969M	1.14B
Order Backlog	86.38B	142B	146B	135B	166B

Fiscal Period: December	2021	2022	2023	2024	2025
Net Income	3.39B	4.42B	3.4B	3.36B	4.91B
Depreciation & Amortization - CF	434M	744M	1.11B	1.38B	1.39B
Amortization of Goodwill and Intangible Assets - (CF)	47.67M	57.07M	61.07M	59.42M	53.78M
Depreciation & Amortization, Total	482M	801M	1.17B	1.44B	1.45B
Amortization of Deferred Charges, Total - (CF)	90.49M	32.36M	-73.88M	24.43M	29.98M
(Gain) Loss From Sale Of Asset	870K	19.27M	3.48M	-456K	635M
(Gain) Loss on Sale of Investments - (CF)	-665M	-379M	-13.83M	91.72M	-1.05B
(Income) Loss On Equity Investments - (CF)	-	-	-	-	-
Stock-Based Compensation (CF)	532M	1.23B	1.27B	1.22B	955M
Provision and Write-off of Bad Debts	157M	259M	320M	152M	205M
Other Operating Activities, Total	410M	130M	-515M	-258M	936M
Change In Accounts Receivable	-1.44B	-1.5B	-1.04B	162M	-2.59B
Change In Inventories	-783M	-498M	442M	202M	6.39M
Change In Accounts Payable	742M	-509M	-162M	375M	797M
Change in Unearned Revenues	1.07B	1.63B	-317M	-1.31B	410M
Change in Other Net Operating Assets	-552M	-100M	178M	-227M	-356M
Cash from Operations	3.43B	5.54B	4.67B	5.22B	6.34B
Capital Expenditure	-6.51B	-5.87B	-4.05B	-3.93B	-3.69B
Sale of Property, Plant, and Equipment	80.86M	20.12M	197M	87.33M	4.18B
Cash Acquisitions	-2.18B	-131M	-	-	-
Sale (Purchase) of Intangible assets	-	-	-10M	-	-50.6M
Investment in Marketable and Equity Securities, Total	-1.43B	-253M	596M	-388M	-3.95B
Other Investing Activities, Total	434M	325M	34.07M	289M	423M
Cash from Investing	-9.6B	-5.91B	-3.23B	-3.94B	-3.09B
Short Term Debt Issued, Total	-	-	-	-	-
Long-Term Debt Issued, Total	675M	2.39B	1.1B	1.13B	1.12B
Total Debt Issued	675M	2.39B	1.1B	1.13B	1.12B
Short Term Debt Repaid, Total	-	-	-	-	-
Long-Term Debt Repaid, Total	-822M	-2.68B	-1.92B	-819M	-2.9B
Total Debt Repaid	-822M	-2.68B	-1.92B	-819M	-2.9B
Issuance of Common Stock	11.04B	36.18M	26.16M	19.39M	163M
Repurchase of Common Stock	-2.52B	-2.8B	-917M	-1.77B	-1.58B
Other Financing Activities, Total	-162M	472M	3.67B	-1.31B	1.03B
Cash from Financing	8.21B	-2.59B	1.96B	-2.75B	-2.16B
Foreign Exchange Rate Adjustments	-132M	350M	-126M	83.98M	-155M
Net Change in Cash	1.91B	-2.61B	3.27B	-1.39B	935M
Supplemental Items
Cash Interest Paid	83.2M	108M	217M	201M	160M
Cash Income Tax Paid (Refund)	350M	586M	783M	1.09B	1.4B
Levered Free Cash Flow	-3.72B	-594M	-320M	-2.3B	4.28B
Unlevered Free Cash Flow	-3.7B	-554M	-221M	-2.2B	4.37B
Change In Net Working Capital	320M	-466M	1.14B	3.81B	-1.51B
Net Debt Issued / Repaid	-147M	-295M	-818M	310M	-1.78B

Fiscal Period: December	2021	2022	2023	2024	2025
Profitability
Return on Assets	5.43	5.81	4.63	5.05	6.88
Return on Total Capital	6.47	7	5.51	5.79	7.8
Return On Equity %	13.09	13.2	8.9	8.82	11.64
Return on Common Equity	12.82	13.13	9.02	8.17	11.02
Margin Analysis
Gross Profit Margin %	46.93	44.04	40.08	40.97	45.98
SG&A Margin	9.72	9.38	10.5	11.5	10.62
EBITDA Margin %	35.2	33.2	28.93	31.32	36.37
EBITA Margin %	31.27	28.86	23.45	24.87	30.75
EBIT Margin %	30.81	28.49	23.09	24.55	30.5
Income From Continuing Operations Margin %	34.1	29.8	20.96	21.13	26.31
Net Income Margin %	32.93	28.95	19.96	17.97	22.53
Net Avail. For Common Margin %	32.93	28.95	19.96	17.97	22.53
Normalized Net Income Margin	19.04	19.53	14.26	13.33	15.85
Levered Free Cash Flow Margin	-36.16	-3.89	-1.88	-12.3	19.66
Unlevered Free Cash Flow Margin	-35.92	-3.63	-1.3	-11.77	20.07
Asset Turnover
Asset Turnover	0.28	0.33	0.32	0.33	0.36
Fixed Assets Turnover	0.63	0.67	0.61	0.64	0.75
Receivables Turnover (Average Receivables)	3.65	3.62	3	3.13	3.22
Inventory Turnover (Average Inventory)	3.94	4.31	5.04	6.71	8.11
Short Term Liquidity
Current Ratio	2.37	1.98	2.78	2.73	3.39
Quick Ratio	1.85	1.55	2.35	1.98	2.96
Operating Cash Flow to Current Liabilities	0.42	0.59	0.61	0.61	0.76
Days Sales Outstanding (Average Receivables)	100.09	100.78	121.52	116.79	113.35
Days Outstanding Inventory (Average Inventory)	92.62	84.76	72.36	54.57	45.01
Average Days Payable Outstanding	38.03	28.2	49.71	26.83	28.85
Cash Conversion Cycle (Average Days)	154.68	157.33	144.17	144.54	129.51
Long Term Solvency
Total Debt/Equity	13.13	12.21	10.36	10.86	5.85
Total Debt / Total Capital	11.61	10.88	9.39	9.8	5.53
LT Debt/Equity	6.33	8.15	8.7	5.1	3.49
Long-Term Debt / Total Capital	5.59	7.26	7.88	4.6	3.29
Total Liabilities / Total Assets	25.72	26.94	22.2	20.18	16.73
EBIT / Interest Expense	80.89	67.57	24.81	29.1	46.46
EBITDA / Interest Expense	93.18	80	32.19	38.22	56.58
(EBITDA - Capex) / Interest Expense	-72.87	-11.15	6.67	13.28	30.83
Total Debt / EBITDA	1.18	0.86	0.89	0.82	0.38
Net Debt / EBITDA	-1.87	-0.83	-1.31	-0.96	-1.56
Total Debt / (EBITDA - Capex)	-1.5	-6.16	4.32	2.36	0.7
Net Debt / (EBITDA - Capex)	2.39	5.98	-6.32	-2.76	-2.86
Growth Over Prior Year
Total Revenues, 1 Yr. Growth %	83.35	48.38	11.56	9.63	16.68
Gross Profit, 1 Yr. Growth %	90.64	39.25	1.54	12.05	30.95
EBITDA, 1 Yr. Growth %	104.51	39.93	-2.77	18.68	35.49
EBITA, 1 Yr. Growth %	109.71	36.97	-9.38	16.3	44.25
EBIT, 1 Yr. Growth %	111.01	37.23	-9.6	16.6	44.95
Earnings From Cont. Operations, 1 Yr. Growth %	107.28	29.68	-21.52	10.5	45.32
Net Income, 1 Yr. Growth %	100.63	30.45	-23.09	-1.28	46.25
Normalized Net Income, 1 Yr. Growth %	97.42	52.16	-18.54	1.09	38.75
Diluted EPS Before Extra, 1 Yr. Growth %	92.5	31.17	-23.5	1.55	47.92
Accounts Receivable, 1 Yr. Growth %	38.07	57.6	19.89	-7.27	36.01
Inventory, 1 Yr. Growth %	55.63	35.18	-22.59	-13.82	-9.23
Net Property, Plant and Equip., 1 Yr. Growth %	53.5	31.18	15.52	-5.02	4.64
Total Assets, 1 Yr. Growth %	52.03	12.56	14.15	0.71	11.79
Tangible Book Value, 1 Yr. Growth %	50.84	9.36	16.14	4.07	13.56
Common Equity, 1 Yr. Growth %	56.96	8.58	15.08	3.69	12.98
Cash From Operations, 1 Yr. Growth %	82.39	61.51	-15.77	11.77	21.54
Capital Expenditures, 1 Yr. Growth %	8.02	-9.83	-31.06	-2.87	-6.22
Levered Free Cash Flow, 1 Yr. Growth %	-37.79	-84.02	-46.11	616.87	-286.57
Unlevered Free Cash Flow, 1 Yr. Growth %	-37.93	-85.01	-60.07	893.3	-299
Compound Annual Growth Rate Over Two Years
Total Revenues, 2 Yr. CAGR %	60.72	64.94	28.66	10.59	13.1
Gross Profit, 2 Yr. CAGR %	70.62	62.93	18.91	6.67	21.13
EBITDA, 2 Yr. CAGR %	78.15	69.17	16.64	7.42	26.81
EBITA, 2 Yr. CAGR %	82.25	69.48	11.41	2.66	29.52
EBIT, 2 Yr. CAGR %	82.87	70.17	11.38	2.67	30
Earnings From Cont. Operations, 2 Yr. CAGR %	86.35	63.95	0.88	-6.88	26.71
Net Income, 2 Yr. CAGR %	82.82	61.78	0.17	-12.87	20.16
Normalized Net Income, 2 Yr. CAGR %	66.68	73.32	11.33	-8.63	18.43
Diluted EPS Before Extra, 2 Yr. CAGR %	75.5	58.9	0.17	-11.86	22.56
Accounts Receivable, 2 Yr. CAGR %	54.18	47.51	37.46	5.44	12.3
Inventory, 2 Yr. CAGR %	105.55	45.04	2.3	-18.32	-11.56
Net Property, Plant and Equip., 2 Yr. CAGR %	70.49	41.9	23.1	4.75	-0.31
Total Assets, 2 Yr. CAGR %	58.16	30.82	13.35	7.22	6.11
Tangible Book Value, 2 Yr. CAGR %	57.31	28.43	12.7	9.94	8.71
Common Equity, 2 Yr. CAGR %	58.9	30.55	11.78	9.23	8.24
Cash From Operations, 2 Yr. CAGR %	68.53	71.63	16.63	-2.97	16.55
Capital Expenditures, 2 Yr. CAGR %	42.37	-1.31	-21.16	-18.17	-4.56
Levered Free Cash Flow, 2 Yr. CAGR %	23.49	-68.47	-70.66	96.55	265.72
Unlevered Free Cash Flow, 2 Yr. CAGR %	23.39	-69.49	-75.53	99.14	344.6
Compound Annual Growth Rate Over Three Years
Total Revenues, 3 Yr. CAGR %	59.53	56.5	44.79	21.98	12.59
Gross Profit, 3 Yr. CAGR %	68.04	59.45	39.17	16.58	14.22
EBITDA, 3 Yr. CAGR %	76.05	64.37	40.65	17.32	16.06
EBITA, 3 Yr. CAGR %	82.16	65.7	37.56	13.02	14.99
EBIT, 3 Yr. CAGR %	82.4	66.18	37.82	13.09	15.18
Earnings From Cont. Operations, 3 Yr. CAGR %	77.21	65.14	28.25	3.99	8.01
Net Income, 3 Yr. CAGR %	75.15	63.37	26.26	-0.32	3.55
Normalized Net Income, 3 Yr. CAGR %	62.03	61.69	34.76	8.3	5.02
Diluted EPS Before Extra, 3 Yr. CAGR %	68.83	59.27	24.54	0.63	4.74
Accounts Receivable, 3 Yr. CAGR %	60.01	55.31	37.66	20.55	14.78
Inventory, 3 Yr. CAGR %	95.11	78.75	17.65	-3.39	-15.4
Net Property, Plant and Equip., 3 Yr. CAGR %	89.48	56.23	32.5	12.91	4.71
Total Assets, 3 Yr. CAGR %	67.36	41.21	25	8.97	8.72
Tangible Book Value, 3 Yr. CAGR %	57.87	39.35	24.2	9.74	11.13
Common Equity, 3 Yr. CAGR %	59.24	39.96	25.17	9.02	10.47
Cash From Operations, 3 Yr. CAGR %	65.16	66.16	35.38	14.99	4.59
Capital Expenditures, 3 Yr. CAGR %	69.32	22.27	-12.43	-15.48	-14.37
Levered Free Cash Flow, 3 Yr. CAGR %	44.25	-37.54	-62.31	-14.86	93.16
Unlevered Free Cash Flow, 3 Yr. CAGR %	43.94	-38.88	-66.63	-15.91	99.1
Compound Annual Growth Rate Over Five Years
Total Revenues, 5 Yr. CAGR %	59.75	56.65	46.38	36.21	31.17
Gross Profit, 5 Yr. CAGR %	65.48	59.05	46.33	35.76	31.65
EBITDA, 5 Yr. CAGR %	62.56	59.04	49.32	38.65	34.94
EBITA, 5 Yr. CAGR %	70.11	60.74	49.64	36.82	34.29
EBIT, 5 Yr. CAGR %	69.6	60.32	49.74	37.06	34.64
Earnings From Cont. Operations, 5 Yr. CAGR %	90.16	78.28	41.45	31.32	27.63
Net Income, 5 Yr. CAGR %	88.84	77.25	40.07	27.05	23.78
Normalized Net Income, 5 Yr. CAGR %	77.92	74.27	39.45	28.69	28.32
Diluted EPS Before Extra, 5 Yr. CAGR %	73.63	68.98	37.02	25.7	23.75
Accounts Receivable, 5 Yr. CAGR %	61.94	75	50.58	33.02	26.9
Inventory, 5 Yr. CAGR %	52.93	46.51	50.7	30.67	4.96
Net Property, Plant and Equip., 5 Yr. CAGR %	76.52	70.85	59.46	33.14	18.25
Total Assets, 5 Yr. CAGR %	85.87	59.19	43.21	26.48	17.07
Tangible Book Value, 5 Yr. CAGR %	156.7	52.29	37.96	26.74	17.75
Common Equity, 5 Yr. CAGR %	160.23	54.17	38.22	26.75	18.1
Cash From Operations, 5 Yr. CAGR %	111.06	72.74	43.71	33.99	27.51
Capital Expenditures, 5 Yr. CAGR %	72.27	54.32	24.72	4.12	-9.36
Levered Free Cash Flow, 5 Yr. CAGR %	46.1	9.22	-23.71	-1.2	-6.46
Unlevered Free Cash Flow, 5 Yr. CAGR %	46.71	9	-29.15	-1.97	-5.98